Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer.
The efficacy and toxicity of weekly low dose chemotherapy using paclitaxel and cisplatin were evaluated in 22 chemotherapy-naïve patients with non-small cell lung cancer (NSCLC). Paclitaxel (40 mg/m(2) by 1 h infusion) and cisplatin (20 mg/m(2) by 1 h infusion) were administered weekly without interruption. With a median of 16 cycles of weekly chemotherapy, objective response rate was 40.9% (95% confidence interval, 18.6-63.2%). Stable disease and progressive disease categories accounted for 40.9 and 18.2%, respectively. The median response duration was 3 months (1-12 months). Myelosuppression was not noted and non-hematologic toxicities were mild. This study indicates that weekly low dose chemotherapy using paclitaxel and cisplatin could be given safely to the patients with NSCLC and showed a promising response rate.
Kim
Sang-We
SW
Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-Dong Songpa-Ku, Seoul 138-736, South Korea. swkim@amc.seoul.kr
Suh
Cheolwon
C
Lee
Sang Do
SD
Kim
Woo Sung
WS
Kim
Dong Soon
DS
Kim
Won Dong
WD
Lee
Jung Sin
JS
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage*; D016896:Treatment Outcome
D017239:Paclitaxel; D002945:Cisplatin